Skip to content
ANAVEX
ANAVEX
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
  • JOIN US
Search
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
  • JOIN US
View allAlzheimer's DiseaseAnavex2-73EventsNews ReleasesPDDPIPELINEPressRett Syndrome

Anavex Comments on New Alzheimer’s Disease Diagnostic Guidelines

May 17, 2011

Anavex Appoints Robert Chisholm to Board of Directors

May 13, 2011

Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders

May 11, 2011

Anavex First-in-Human Dosing Commenced in ANAVEX 2-73 Clinical Trial for Alzheimer’s Disease

April 20, 2011

Anavex Appoints Dr. Christopher Shackleton as an Advisor

April 8, 2011

Anavex to Hold Annual Meeting on April 11, 2011

April 6, 2011

Anavex Screening Healthy Volunteers for Phase I, First-in-Human Clinical Study in Alzheimer’s disease

March 31, 2011

Anavex Management to Hold Live Investor Conference Call Today at 4:30PM ET

March 16, 2011

Anavex Receives Approval to Commence Phase I Clinical Trial in Alzheimer’s Disease

March 15, 2011

Anavex Appoints Dr. Jeffrey Cummings to its Scientific Advisory Board

March 1, 2011

Anavex Appoints Independent Director

February 24, 2011

Anavex Appoints Dr. Rachelle Doody to Scientific Advisory Board

February 23, 2011
1
23456789101112131415161718192021222324252627
…2829303132…
33343536373839404142
43

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2019 All Rights Reserved

Go to Top